A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab

The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total patho...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Charlie, Khwaja, Raida, Tang, Patricia, Nixon, Nancy, King, Karen, Lupichuk, Sasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221768/
https://www.ncbi.nlm.nih.gov/pubmed/35735446
http://dx.doi.org/10.3390/curroncol29060337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221768/
https://www.ncbi.nlm.nih.gov/pubmed/35735446
http://dx.doi.org/10.3390/curroncol29060337

Ejemplares similares